CHEK2 and renal cell carcinoma: Although there is now increasing evidence that CHEK2 germline mutations are associated with an increased risk of RCC, larger case-control studies in patients with RCC are needed to confirm and refine the magnitude of the associated risk (Stolarova et al., 2020).